In conclusion, our study highlights the importance of early severe infections and death in the era of novel agent-based therapy in patients with NDMM. Based on our risk score, patients at high risk of early, severe infections and death can be easily identified upfront, when evaluated for the latest quadruplet induction therapies including an anti-CD38 mAb.